JSPR250117C22500
- 5.10
- +0.50+10.87%
Jasper Therapeutics Newsroom
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $63
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $60 to $70
Promising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in Briquilimab
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Buy Rating on Jasper Therapeutics Backed by Strategic Clinical Program Expansion and Promising Preliminary Results
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $55 to $90
Jasper Therapeutics Analyst Ratings
Buy Rating Affirmed for Jasper Therapeutics Amidst Promising Briquilimab Clinical Data and Market Potential